Uterine artery chemoembolization compared with uterine artery embolization combined with prior to hysteroscopy and curettage in the treatment of cesarean scar pregnancy

子宫动脉化疗栓塞术与子宫动脉栓塞术联合宫腔镜刮宫术治疗剖宫产瘢痕妊娠的比较

阅读:1

Abstract

BACKGROUND: To compare evaluate the clinical effectiveness and safety efficacy of uterine artery chemoembolization (UACE) and versus uterine artery embolization (UAE) prior to combined with hysteroscopy and curettage in the treatment of cesarean scar pregnancy (CSP). METHODSOLOGY: A total The clinical data of 84 patients with CSP who underwent UACE or U AE combined with hysteroscopy and-guied uterine curettage were enrolled in the retrospective cohort study from August 2016 to April 2021 were retrospectively collected. They were divided into UACE group (n = 39) and UAE group (n = 45) according to different surgical methods. The clinical characteristics general data, operat treatment success rate, ion, postoperative outcome conditions, and re-pregnancy productive outcomes of the two groups were observed and compared and analyzed between the two groups. RESULTS: The overall success rate of 84 patients was 96.43%, the complication rate was 19.05%, and the serious complication rate was 1.19%. There was no significant difference between the two groups in the success rate of operation, complication rate, serious complication rate, UAE operativeon time, hysteroscopic operation time, intraoperative bleeding volume, duration of postoperative hospital stay, β-human chorionic gonadotropin (β-hCG) reduction decrease on postoperative day 1, and re-pregnancy productive outcome (P > 0.05). The time of menstruation recoveryto resumption of menses was shorter in the UACE group than in the UAE group (P < 0.05). CONCLUSION: UACE was as effective and safe as UAE in the treatment of CSPor UAE combined with hysteroscopy is safe and effective in the treatment of CSP, and the time of menstruation recovery was shorter. UACE reduced the time to resumption of menses compared with UAE, with a similar both of which had similar re-pregnancy productive outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。